Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AMP-ing up disease recurrence detection
May 2019
SHARING OPTIONS:

BOULDER, Colo.—ArcherDX Inc., the University College London (UCL) and the Francis Crick Institute joined forces in a research collaboration lately to pursue a new method of detecting disease recurrence in patients with lung cancer. The partners will leverage ArcherDX’s proprietary Anchored Multiplex PCR (AMP) technology to detect evidence of cancer recurrence in patients from cell-free circulating tumor DNA (ctDNA) within the auspices of the TRACERx clinical study, which is funded by Cancer Research UK and sponsored by UCL. Preliminary results from the study showed that with a patient-specific approach, ctDNA profiling could be used to determine minimal residual disease (MRD) in patients who had undergone potentially curative surgery. The three organizations plan to explore the results by developing assays based on AMP technology to detect low-volume MRD at high sensitivity.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.